The ultimate goal of this project continues to be: to overcome tumor resistance to the anticancer drug bleomycin (BLM) and to broaden the spectrum of human cancers that can be treated with BLM. The overall objective is to investigate the role of the BLM-inactivating enzyme, BLM hydrolase, in the resistance of human tumors to BLM and to develop strategies to overcome this resistance. This will be accomplished by a) cloning and sequencing human tumor BLM hydrolase cDNA, transfecting this cDNA into BLM-sensitive tumor cells and determining their responsiveness to BLM b) introducing a neutralizing BLM hydrolase antibody to BLM- resistant cells and determining their responsiveness to BLM, c) investigating the mechanism by which some human tumors metabolize higher levels of BLM, determining the levels of BLM hydrolase activity, its gene expression, protein amount and turnover rate in human tumors, and relating these parameters to the antitumor activity of BLM in these tumors, d) determining the metabolic pathways involved in the complex BLM metabolism observed in human tumors, sensitizing these tumors using inhibitors of BLM metabolism, and e) isolating and characterizing the various BLM metabolites formed in human tumors. Cloning of the full length BLM hydrolase cDNA will be carried out using a partial length BLM hydrolase cDNA insert that we have recently isolated from a Burkitt's lymphoma cDNA library. This probe will also be used to determine gene expression levels of BLM hydrolase in human tumor cells. Neutralization of intracellular BLM hydrolase will be carried out by electroporation of BLM-resistant human tumor cells with affinity-purified antibody that we have recently prepared against a 14 amino acid BLM hydrolase peptide. This neutralizing antibody will also be used to measure tumor content of BLM hydrolase. BLM hydrolase activity will be measured by high performance liquid chromatography. The in vivo antitumor studies will be carried out using human tumor cell lines with various degrees of BLM- resistance in the nude mouse xenograft model. Human tumor cell lines, including those transfected with BLM hydrolase cDNA, and human tumor fragments from fresh biopsies, will be implanted subcutaneously into athymic nude mice and examined for their responsiveness to BLM and for their BLM hydrolase content, activity and expression levels. These studies will enhance our understanding of the mechanism by which BLM hydrolase levels influence the responsiveness of human tumors to BLM treatment and will allow us to develop strategies to overcome BLM resistance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA048905-05
Application #
2093093
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1990-01-01
Project End
1996-12-31
Budget Start
1994-01-01
Budget End
1994-12-31
Support Year
5
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Pharmacology
Type
Schools of Dentistry
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Pei, Z; Sebti, S M (1996) Cys102 and His398 are required for bleomycin-inactivating activity but not for hexamer formation of yeast bleomycin hydrolase. Biochemistry 35:10751-6
Pei, Z; Calmels, T P; Creutz, C E et al. (1995) Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells. Mol Pharmacol 48:676-81
Morris, G; Mistry, J S; Jani, J P et al. (1992) Neutralization of bleomycin hydrolase by an epitope-specific antibody. Mol Pharmacol 42:57-62
Jani, J P; Mistry, J S; Morris, G et al. (1992) In vivo circumvention of human colon carcinoma resistance to bleomycin. Cancer Res 52:2931-7
Jani, J P; Mistry, J S; Morris, G et al. (1992) In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64. Oncol Res 4:59-63
Mistry, J S; Jani, J P; Morris, G et al. (1992) Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b. Cancer Res 52:709-18
Sebti, S M; Jani, J P; Mistry, J S et al. (1991) Metabolic inactivation: a mechanism of human tumor resistance to bleomycin. Cancer Res 51:227-32
Morris, G; Mistry, J S; Jani, J P et al. (1991) Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells. Biochem Pharmacol 41:1559-66